Company News »

Imprivata, Inc. Reports Third Quarter 2014 Financial Results

Business Wire
Share on StockTwits
Published on

Imprivata(R) (NYSE:IMPR) , a leading provider of authentication and access management solutions for the healthcare industry, today announced financial results for the third quarter of fiscal 2014. Revenues for the third quarter were $25.3 million, an increase of 41% from revenues of $17.9 million for the same period in 2013. Revenues for the nine months ended September 30, 2014 were $68.0 million, an increase of 37% from revenues of $49.5 million for the same period in 2013.

Omar Hussain, CEO of Imprivata, commented, “Our record third quarter revenues were driven by both new and existing customers, along with key competitive takeaways. We continue to see strong demand in our business driven by Meaningful Use Stage 2 initiatives, hospitals deploying Virtual Desktop Infrastructures, and the increasing adoption of EMRs globally. Our growth and success continue to validate that Imprivata solutions are important to our customers as they balance IT security with provider productivity.”

Net loss for the third quarter of 2014 was $4.5 million, or $(0.19) per basic and diluted share attributable to common stockholders, as compared to a net loss of $0.7 million, or $(0.54) per basic and diluted share attributable to common stockholders for the same period in 2013. Net loss for the nine months ended September 30, 2014 was $15.1 million, or $(1.64) per basic and diluted share attributable to common stockholders, as compared to a net loss of $2.3 million, or $(1.82) per basic and diluted share attributable to common stockholders for the same period in 2013. Consistent with our operating results for the first half of 2014, the quarterly loss represents our continued strategic investments in the business to maintain our market leadership position and capture additional market share, as well as develop new complementary products to our existing product portfolio.

Adjusted EBITDA(1) for the third quarter of 2014 was a loss of $2.8 million, as compared to a loss of $0.8 million for the same period in 2013. Non-GAAP net loss (2) for the third quarter of 2014 was $3.8 million, or $(0.16) per basic and diluted share, as compared to non-GAAP net loss of $1.2 million, or $(0.34) per basic share and diluted share, for the same period in 2013. Adjusted EBITDA for the nine months ended September 30, 2014 was a loss of $11.5 million, as compared to a loss of $0.9 million for the same period in 2013. Non-GAAP net loss for the nine months ended September 30, 2014 was $14.0 million, or $(1.31) per basic and diluted share, as compared to non-GAAP net loss of $2.2 million, or $(0.68) per basic and diluted share, for the same period in 2013. A reconciliation of GAAP to these non-GAAP financial measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

(1) Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted for foreign currency gains (losses), stock based-compensation and the impact of the fair value revaluation on our contingent liability.
(2) Non-GAAP net income (loss) and non-GAAP net income (loss) per share excludes amortization of purchased intangible assets, stock-based compensation and the impact of the fair value revaluation on our contingent liability.

Fourth Quarter and Full-Year 2014 Financial Outlook

For the full-year, we expect revenue between $94 million and $95 million and Adjusted EBITDA to be between a loss of $14 million and $13 million. In terms of earnings per share, we expect GAAP loss to be between $1.51 per share and $1.47 per share and non-GAAP loss, which adjusts for stock-based compensation, amortization of purchased intangible assets and the contingent liability revaluation, to be between $1.19 per share and $1.16 per share. Our annual EPS estimates are based on an estimated weighted average-share count of 13.9 million.

For the fourth quarter, we expect revenue between $26 million and $27 million and Adjusted EBITDA to be between a loss of $2.0 million and $1.0 million. In terms of earnings per share, we expect GAAP loss to be between $0.15 per share and $0.13 per share and non-GAAP loss to be between $0.11 per share and $0.09 per share. Our fourth quarter EPS estimates are based on an estimated weighted average-share count of 23.7 million.

Conference Call Information

Imprivata management will host a conference call at 5:00 pm (Eastern Time) on Monday, November 3, 2014 to discuss the Company’s third quarter 2014 results, its business outlook and other matters. The conference call will be accessible by dialing (888) 364-3108, or (719) 325-2464 for international callers, and referencing conference ID number 7055889. A live webcast of the conference call will also be available on the investor relations section of the company’s website at www.imprivata.com.

An audio replay will be available following the conclusion of the call through November 17, 2014. The replay can be accessed by dialing (888) 203-1112 in the U.S., or +1 (719) 457-0820 for international callers. The passcode for the replay is: 7055889.

About Imprivata

Imprivata, Inc. (NYSE:IMPR) headquartered in Lexington, Massachusetts, is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s flagship solution, Imprivata OneSign(R), is an integrated enterprise single sign-on, authentication and access management and workflow automation platform that addresses multiple security and productivity challenges faced by hospitals and other healthcare organizations. For more information, please visit www.imprivata.com.

All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our customer base and our overall business, our market opportunity, our goal to maintain market leadership and our expected financial results for Q4 2014 and the full fiscal year 2014. All statements other than statements of historical fact contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “could,” “increases,” “improves,” “reduces,” “implements,” “results,” “addresses,” or the negative of these terms or other comparable terminology. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Imprivata’s control. Imprivata’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, our ability to successfully develop and introduce new solutions and products for existing solutions; our ability to attract new customers and retain and increase sales to existing customers; developments in the healthcare industry or regulatory environment; seasonal variations in the purchasing patterns of our customers; the lengthy and unpredictable sales cycles for new customers; our ability to maintain successful relationships with our channel partners and technology alliance partners; our dependency on sole source suppliers and a contract manufacturer for hardware components of our Imprivata OneSign solution; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of protected health information; our ability to protect our intellectual property rights, and the other risks detailed in Imprivata’s risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to Imprivata’s Registration Statement on Form S-1 declared effective by the SEC on June 24, 2014, as well as other documents that may be filed by Imprivata from time to time with the SEC. The forward-looking statements included in this press release represent Imprivata’s views as of the date of this press release. Imprivata undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-GAAP Financial Measures

Imprivata has provided in this release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA, non-GAAP net income (loss) and non-GAAP net income (loss) per share. These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Imprivata believes that the use of these non-GAAP financial measures provides supplementary information for investors to use in evaluating operating performance and in comparing its financial measures with other companies in Imprivata’s industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA (EBITDA adjusted for foreign currency gains (losses), stock based-compensation and the impact of the fair value revaluation on our contingent liability), non-GAAP net income (loss) and non-GAAP net income (loss) per share exclude amortization expense associated with our purchased intangible assets, stock-based compensation and the impact of the re-measurement to fair value of our contingent liability. Non-GAAP financial measures that Imprivata uses may differ from measures that other companies may use. These non-GAAP financial measures disclosed by Imprivata are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

Imprivata, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
Three Months Nine Months
Ended Ended
September 30, September 30,
2014 2013 2014 2013
Revenue
Product $ 14,133 $ 10,017 $ 35,632 $ 26,923
Maintenance and services 11,145 7,890 32,320 22,554
Total revenue 25,278 17,907 67,952 49,477
Cost of revenue
Product 4,287 1,753 8,922 4,923
Maintenance and services 4,353 2,779 12,946 7,525
Total cost of revenue 8,640 4,532 21,868 12,448
Gross profit 16,638 13,375 46,084 37,029
Operating expenses
Research and development 6,425 4,923 19,252 13,376
Sales and marketing 11,129 7,368 32,764 20,827
General and administrative 3,162 1,767 8,486 5,136
Total operating expenses 20,716 14,058 60,502 39,339
Income (loss) from operations (4,078 ) (683 ) (14,418 ) (2,310 )
Other income (expense)
Interest and other income (expense), net (344 ) 66 (536 ) 120

Loss before income taxes

(4,422 ) (617 ) (14,954 ) (2,190 )
Income taxes (benefit) 32 33 119 74
Net loss (4,454 ) (650 ) (15,073 ) (2,264 )
Accretion of redeemable convertible preferred stock (1,238 ) (2,442 ) (3,714 )
Net loss attributable to common stockholders $ (4,454 ) $ (1,888 ) $ (17,515 ) $ (5,978 )
Net loss per share attributable to common stockholders
Basic and diluted $ (0.19 ) $ (0.54 ) $ (1.64 ) $ (1.82 )
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders
Basic and diluted 23,706 3,490 10,654 3,288
Imprivata, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
September 30, December 31,
2014 2013
Assets
Current assets:
Cash and cash equivalents $ 78,037 $ 13,284
Accounts receivable, net of allowances 19,284 19,754
Prepaid expenses and other current assets 3,782 2,541
Total current assets 101,103 35,579
Property and equipment, net 8,142 6,682
Goodwill 1,560 1,560
Intangible assets, net 1,615 2,000
Other assets 103 649
Total assets $ 112,523 $ 46,470
Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
Current liabilities:
Accounts payable $ 2,981 $ 3,586
Accrued expenses and other current liabilities 8,123 9,149
Current portion of capital lease obligations and long-term debt 666 313
Current portion of other long-term liabilities 288 249
Current portion of deferred revenue 28,249 25,084
Total current liabilities 40,307 38,381
Deferred revenue, net of current portion 4,302 3,490
Capital lease obligations, long-term debt and royalty obligations, net of current portion 759 410
Other long-term liabilities, net of current portion 1,153 1,181
Contingent purchase price liability 560 1,008
Total liabilities 47,081 44,470
Commitments and contingencies
Redeemable convertible preferred stock 91,607
Stockholders’ equity (deficit):
Undesignated preferred stock

Common stock 24 4
Additional paid-in capital 171,366
Accumulated other comprehensive loss (60 ) (145 )
Accumulated deficit (105,888 ) (89,466 )
Total stockholders’ equity (deficit) 65,442 (89,607 )
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) $ 112,523 $ 46,470
Imprivata, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Nine Months Ended
September 30,
2014 2013
Cash flows from operating activities:
Net Loss $ (15,073 ) $ (2,264 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense 2,241 1,747
Provision for doubtful accounts 90 57
Stock-based compensation 1,126 409
Loss on disposal of fixed assets 66 16
Change in value of contingent purchase price liability (448 ) (784 )
Changes in operating assets and liabilities
Accounts receivable 380 (322 )
Prepaid expenses and other current assets (856 ) (1,092 )
Other assets 18
Deferred revenue 3,977 2,781
Accounts payable (723 ) (1,795 )
Accrued expenses and other current liabilities (201 ) (520 )
Other liabilities 12 (192 )
Net cash used in operating activities (9,409 ) (1,941 )
Cash flows from investing activities:
Purchases of property and equipment (2,723 ) (1,781 )
Restricted cash 97
Net cash used in investing activities (2,723 ) (1,684 )
Cash flows from financing activities:
Proceeds from initial public offering, net of underwriting discounts and commissions 80,213
Deferred offering costs (3,287 )
Repayments for capital lease obligations, long-term debt and other (497 ) (238 )
Proceeds from exercise of stock options 448 812
Net cash provided by financing activities 76,877 574
Effect of exchange rates on cash and cash equivalents 8 (129 )
Net increase (decrease) in cash and cash equivalents 64,753 (3,180 )
Cash and cash equivalents, beginning of period 13,284 15,410
Cash and cash equivalents, end of period $ 78,037 $ 12,230
Imprivata, Inc.
Non-GAAP Financial Measures
(in thousands, except per share amounts)
(unaudited)
Reconciliation of GAAP Net Loss to Adjusted EBITDA
Three Months Nine Months
Ended Ended
September 30, September 30,
2014 2013 2014 2013
GAAP net loss $ (4,454 ) $ (650 ) $ (15,073 ) $ (2,264 )
Adjustments to reconcile to Adjusted EBITDA:
Income tax expense 32 33 119 74
Depreciation and amortization 783 584 2,241 1,747
Other expense (income), net 344 (66 ) 536 (120 )
Stock-based compensation 461 152 1,126 409
Change in fair value of contingent liability 16 (815 ) (448 ) (784 )
Adjusted EBITDA $ (2,818 ) $ (762 ) $ (11,499 ) $ (938 )
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss and Non-GAAP Net Loss Per Share (a)
Three Months Nine Months
Ended Ended
September 30, September 30,
2014 2013 2014 2013
GAAP net loss $ (4,454 ) $ (650 ) $ (15,073 ) $ (2,264 )
Adjustments to reconcile to Non-GAAP net income:
Amortization of purchased intangible assets 128 129 385 393
Stock-based compensation 461 152 1,126 409
Change in fair value of contingent liability 16 (815 ) (448 ) (784 )
Non-GAAP net loss $ (3,849 ) $ (1,184 ) $ (14,010 ) $ (2,246 )
Non-GAAP net loss per share
Basic and diluted $ (0.16 ) $ (0.34 ) $ (1.31 ) $ (0.68 )
Weighted average common shares outstanding used in computing non-GAAP net loss per share
Basic and diluted 23,706 3,490 10,654 3,288
(a) The Company reconciles non-GAAP net loss per share beginning with GAAP net loss instead of GAAP net loss attributable to common stockholders in order to eliminate the effect of the accretion of preferred stock on the calculation.

Share on StockTwits